Technical Analysis for CARM - Carisma Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 1.00 | 2.72% | 0.03 |
CARM closed up 2.72 percent on Friday, November 1, 2024, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Nov 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Flat | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 50 DMA Resistance | Bearish | 2.72% | |
| 20 DMA Support | Bullish | 2.72% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Stochastic Sell Signal | Bearish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Stochastic Reached Overbought | Strength | -0.99% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 20 hours ago |
| 60 Minute Opening Range Breakdown | about 20 hours ago |
| 50 DMA Resistance | about 22 hours ago |
| 60 Minute Opening Range Breakout | about 23 hours ago |
| Rose Above 50 DMA | about 23 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
Carisma Therapeutics Inc. is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania*, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Solid Tumors Immune System Cell Therapy Chimeric Antigen Receptor T Cell Natural Killer Cell Antigen Induced Stem Cells
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Solid Tumors Immune System Cell Therapy Chimeric Antigen Receptor T Cell Natural Killer Cell Antigen Induced Stem Cells
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.4179 |
| 52 Week Low | 0.8 |
| Average Volume | 122,223 |
| 200-Day Moving Average | 1.51 |
| 50-Day Moving Average | 1.00 |
| 20-Day Moving Average | 0.97 |
| 10-Day Moving Average | 0.99 |
| Average True Range | 0.05 |
| RSI (14) | 52.38 |
| ADX | 14.66 |
| +DI | 24.76 |
| -DI | 18.23 |
| Chandelier Exit (Long, 3 ATRs) | 0.93 |
| Chandelier Exit (Short, 3 ATRs) | 1.03 |
| Upper Bollinger Bands | 1.04 |
| Lower Bollinger Band | 0.90 |
| Percent B (%b) | 0.71 |
| BandWidth | 13.71 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0044 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.06 | ||||
| Resistance 3 (R3) | 1.06 | 1.04 | 1.05 | ||
| Resistance 2 (R2) | 1.04 | 1.02 | 1.04 | 1.05 | |
| Resistance 1 (R1) | 1.02 | 1.02 | 1.02 | 1.02 | 1.04 |
| Pivot Point | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Support 1 (S1) | 0.98 | 0.99 | 0.98 | 0.98 | 0.96 |
| Support 2 (S2) | 0.96 | 0.98 | 0.96 | 0.95 | |
| Support 3 (S3) | 0.94 | 0.96 | 0.95 | ||
| Support 4 (S4) | 0.94 |
